A Case Series of Choroidal and Orbital Neuroendocrine Tumors: Metastasis: Two Patients Treated With Peptide...

Area of Science:

• Oncology
• Ophthalmology
• Nuclear Medicine

Background:

• Neuroendocrine tumors (NETs) are rare and diverse cancers, often originating in the GI tract and spreading to the liver.
• Ocular metastases from NETs, particularly to the choroid, are exceptionally uncommon.
• Limited data exists on treatment efficacy and safety for NETs with ocular involvement.

Purpose of the Study:

• To report a series of patients with low-grade NETs presenting with rare choroidal metastases.
• To evaluate the safety and potential efficacy of peptide receptor radionuclide therapy (PRRT) in this specific patient cohort.
• To establish a precedent for PRRT use in NETs with ocular metastases.

Main Methods:

• Case series of 5 patients diagnosed with low-grade NETs and confirmed choroidal metastases.
• Review of treatment protocols and patient outcomes.
• Two patients received treatment with lutetium-177 (177Lu)-based PRRT.

Main Results:

• Five cases of low-grade NETs with choroidal metastases were identified.
• Two patients treated with 177Lu-PRRT tolerated the therapy well.
• No adverse events related to PRRT were observed in the treated patients.

Conclusions:

• This is the first report demonstrating the safety of PRRT in patients with low-grade NETs and ocular metastases.
• PRRT may be a viable and safe treatment option for NET patients with rare choroidal metastases.
• Further research is warranted to assess the long-term efficacy of PRRT in this setting.